The Medical Briefing Nephrology
Anti-rituximab antibodies, dapagliflozin after cardiac surgery, protein intake and GFR, SIAD: urea or tolvaptan
Retrospective no. 1/12
The essentials in four articles
■ Glomerular disease
Among 58 rituximab-naïve patients, 19% developed anti-rituximab antibodies (median 9.3 months), with relapse in 80% versus 24% without antibodies. All 4 resistant antibody-positive patients treated with obinutuzumab achieved remission.
■ AKI and critical care
784 patients, 4 doses of dapagliflozin started the day before surgery: AKI at day 7 in 28% versus 52% with placebo (RR 0.54; NNT ≈ 4), mostly stages 1 and 2, with no difference in major kidney events at day 30 or in length of stay.
■ CKD and dialysis
1,324 adults, GFR measured by iohexol clearance, 10-year follow-up: no association between protein intake (mean 1.2 g/kg/day) and GFR slope. The absence of association does not demonstrate the safety of very high-protein diets.
■ Clinical nephrology
537 patients with serum sodium < 130 mmol/L: comparable efficacy (79.7% vs 78.0%). Tolvaptan corrects faster but causes three times more overcorrection (10.8% vs 3.2%), at a cost of €468 versus €12.